Pancreatic Cancer Research

ResearcherGlasgow Royal InfirmaryNo recent work listed

C. Ross Carter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4956-7991; OpenAlex author ID A5004190449, A5025649086, A5046953795. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 3 papers · 2014: 2 papers · 2015: 3 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper

Papers 17

  1. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  2. Recommended Workflow Methodology in the Creation of an Interactive Application for Patient's Diagnosed with Pancreatic Cancer. First author DOI 10.1007/978-3-030-24281-7_8↗
  3. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Co-author DOI 10.21037/cco.2019.04.06↗
  4. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  5. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  6. Targeting inflammation in pancreatic cancer: Clinical translation. Last author DOI 10.4251/wjgo.v8.i4.380↗
  7. RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Co-author DOI 10.1093/jnci/djv204↗
  8. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. Co-author DOI 10.1371/journal.pone.0131344↗
  9. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  10. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Co-author DOI 10.1053/j.gastro.2014.01.046↗
  11. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  12. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s11605-012-2131-z↗
  13. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11605-013-2168-7↗
  14. Exploiting inflammation for therapeutic gain in pancreatic cancer. Last author DOI 10.1038/bjc.2013.24↗
  15. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarc… Co-author DOI 10.1158/1078-0432.ccr-11-0679↗
  16. The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1245/s10434-012-2370-y↗
  17. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. First author DOI 10.1158/1078-0432.ccr-10-3284↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nigel Balfour Jamieson · 15 shared papers, 2011–2020 · strength 0.70
  2. Colin J. McKay · 12 shared papers, 2011–2020 · strength 0.54
  3. David Kuang-Fu Chang · 5 shared papers, 2014–2020 · strength 0.26
  4. Andrew Victor Biankin · 5 shared papers, 2014–2020 · strength 0.26
  5. Colin William Steele · 5 shared papers, 2013–2016 · strength 0.25
  6. Karin A. Oien · 7 shared papers, 2011–2015 · strength 0.25
  7. Jennifer P. Morton · 7 shared papers, 2012–2016 · strength 0.25
  8. Owen James Sansom · 6 shared papers, 2012–2016 · strength 0.21
  9. Stephan B. Dreyer · 2 shared papers, 2019–2020 · strength 0.15
  10. Peter J. Bailey · 3 shared papers, 2015–2020 · strength 0.15
  11. Olivia M. Knight · 1 shared paper, 2019 · strength 0.14
  12. Paul Rea · 1 shared paper, 2019 · strength 0.14
  13. Thomas R. Jeffry Evans · 4 shared papers, 2012–2016 · strength 0.14
  14. Christopher James Scarlett · 2 shared papers, 2014–2020 · strength 0.10
  15. Donald C. McMillan · 2 shared papers, 2012–2015 · strength 0.08
  16. Lisa Evers · 1 shared paper, 2019 · strength 0.08
  17. Jeremy L. Humphris · 1 shared paper, 2020 · strength 0.07
  18. Jaswinder Singh Samra · 1 shared paper, 2020 · strength 0.07
  19. James G. Kench · 1 shared paper, 2020 · strength 0.07
  20. Angela S. Y. Chou · 1 shared paper, 2020 · strength 0.07
  21. Nam Quoc Nguyen · 1 shared paper, 2020 · strength 0.07
  22. Thomas Knösel · 1 shared paper, 2020 · strength 0.07
  23. Amber L. Johns · 1 shared paper, 2020 · strength 0.07
  24. Marina Pajic · 1 shared paper, 2020 · strength 0.07
  25. Venessa T. Chin · 1 shared paper, 2020 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.